KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Treasury Shares: 2017-2025

Historic Treasury Shares for Guardant Health (GH) over the last 1 years, with Sep 2025 value amounting to $45.0 million.

  • Guardant Health's Treasury Shares fell 80.34% to $976,351 in Q3 2025 from the same period last year, while for Sep 2025 it was $976,351, marking a year-over-year decrease of 80.34%. This contributed to the annual value of $7.0 million for FY2024, which is 61.50% up from last year.
  • As of Q3 2025, Guardant Health's Treasury Shares stood at $45.0 million, which was down 0.00% from $45.0 million recorded in Q2 2025.
  • Guardant Health's Treasury Shares' 5-year high stood at $7.0 million during Q4 2024, with a 5-year trough of $976,351 in Q1 2025.
  • Its 3-year average for Treasury Shares is $3.6 million, with a median of $3.4 million in 2023.
  • As far as peak fluctuations go, Guardant Health's Treasury Shares spiked by 362.40% in 2021, and later crashed by 81.36% in 2025.
  • Guardant Health's Treasury Shares (Quarterly) stood at $1.5 million in 2021, then soared by 146.10% to $3.7 million in 2022, then increased by 17.87% to $4.3 million in 2023, then skyrocketed by 61.50% to $7.0 million in 2024, then plummeted by 80.34% to $976,351 in 2025.
  • Its Treasury Shares stands at $45.0 million for Q3 2025, versus $45.0 million for Q2 2025 and $45.0 million for Q1 2025.